Track topics on Twitter Track topics that are important to you
The tumor microenvironment consists of a heterogenous population of cells which includes tumor cells and tumor-associated stroma cells (TASCs). The TASCs promote tumor angiogenesis, proliferation, invasion and metastasis. Because stroma cells are found in both healthy and cancerous tissue, targeting the tumor stroma has been difficult due to the lack of targets with high tumor specificity. TEM8 (also known as ANTXR1) is a cell surface tumor endothelial marker that is most highly expressed in human tumor-associated stroma of pancreatic, breast, colon, lung, esophageal, bladder, and ovarian cancers. While low levels of expression are seen in healthy kidney, lung, and brain tissue, preliminary toxicity studies suggest limited, if any, toxic effects in these tissues. This differential expression makes TEM8 an attractive potential target for ADC development due to the ability to selectively target TASCs in many different tumor types.
Researchers at the National Cancer Institute (NCI) have developed fully human monoclonal antibodies and antibody-drug conjugates (ADCs) that target TEM8. The antibodies and ADCs have been tested both in vitro and in vivo and have shown promising data. Monomethyl auristatin E (MMAE)-conjugated TEM8 ADCs led to the eradication of large established tumors and metastases and improved long-term overall survival in mouse models. In addition, the ADC was evaluated in preliminary toxicology studies where it showed limited off-target toxicity.
Pre-clinical (in vivo)
C. Szot et al. Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release.
Licensing and research collaboration
Pancreatitis Acute pancreatitis is inflammation of the pancreas caused by the release of activated pancreatic enzymes. Common triggers are biliary tract disease and chronic heavy alcohol intake. Diagnosis is based on clinical presentation...
Track and monitor developments in breast cancer research and commercial development. Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...